VERAXA Biotech AG (NASDAQ: VRXA) has appointed Carl von Halem as interim chief financial officer, succeeding Torsten Bürgermeister, the company announced. The move comes as VERAXA, a biotechnology company focused on antibody-based therapeutics, prepares for its next phase of growth. The company stated that it is in the final stages of discussions with a permanent CFO candidate expected to support its expansion and operational growth, with an update to be provided in due course.
Von Halem currently serves as chief financial officer of Xlife Sciences and played a key role in VERAXA’s public listing. The company cited his experience in corporate finance, life sciences and technology-driven businesses, as well as his familiarity with VERAXA’s operations and strategic development, as key qualifications for leading the finance function during the transition. His appointment ensures continuity in financial leadership while the company evaluates a long-term successor.
VERAXA is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company leverages transformative technologies and quality-by-design principles to advance its pipeline of ADCs and proprietary BiTAC formats into clinical development. Founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), VERAXA aims to address significant unmet medical needs through its innovative approach.
The leadership change underscores VERAXA’s commitment to strengthening its financial team as it progresses toward key milestones. Investors can view the full press release at https://nnw.fm/BjjY6. For more information about VERAXA, visit the company’s newsroom at http://nnw.fm/VRXA.
